// questions
Ipamorelin questions, answered straight from the studies.
Direct answers, numbers attached, every quantitative claim cited.
Does ipamorelin increase IGF-1?
Not always, and that is part of what makes it distinctive. Short rat bone-growth studies measured faster skeletal growth with no measurable change in total IGF-1 [2]. Over sustained or combined protocols IGF-1 can rise — an observational report of growth-hormone-secretagogue combinations in hypogonadal men found elevated serum IGF-1 [13]. So the answer depends on duration and context, not a simple yes.
Does ipamorelin build muscle?
No controlled human trial has tested ipamorelin for muscle growth. The closest data is preclinical: ipamorelin raised maximum tetanic muscle tension in steroid-treated rats [4], and a 2026 review reported CJC-1295 plus ipamorelin improved tetanic tension in a glucocorticoid muscle-loss model in mice while stressing the evidence is animal-only [16]. Community reports of recovery are anecdotal, covered on the effects page.
Is ipamorelin good for bones?
In rats, the skeletal data is the strongest part of the record. Subcutaneous ipamorelin at 18, 90 and 450 microg/day raised longitudinal bone growth rate from 42 to 44, 50 and 52 microm/day, stepwise with dose [2]. Continuous dosing for 12 weeks raised total bone mineral content [3], and it partly rescued steroid-suppressed bone formation [4]. All preclinical — no human bone outcome data exists.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the ghrelin receptor (GHS-R1a) [1]. It releases growth hormone potently without raising cortisol or prolactin, which made it the first selective growth-hormone secretagogue [1]. It is a research chemical, not an approved drug, and was originally developed under the code NNC 26-0161.
What does ipamorelin do for you?
In studies, ipamorelin triggers a single clean pulse of growth hormone by activating the ghrelin receptor on the pituitary [1], and in rats it drives faster bone growth [2] and higher bone mineral content [3]. What it does "for you" specifically is unproven — there is no approved human indication, and the only Phase 2 trial missed its endpoint [7]. Reported human effects are anecdotal.
What is ipamorelin peptide?
Ipamorelin peptide is a five-amino-acid synthetic chain that mimics ghrelin at the GHS-R1a receptor to release growth hormone selectively [1]. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, includes a non-natural Aib residue and D-amino acids for protease resistance [1]. Molecular formula C38H49N9O5, weight near 711.85 Da. It is supplied as a lyophilized research powder.
What are the risks of ipamorelin?
The honest answer is that long-term human risk is uncharacterized. The single Phase 2 RCT (NCT00672074, n=114, 7-day IV) showed no ipamorelin-specific safety signal but missed efficacy [7]. A 28-day study of a related ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats [9]. Mechanistic cautions around IGF-1, glucose, and appetite are detailed, cited, on the effects page.
Does ipamorelin reduce belly fat?
There is no human trial showing ipamorelin reduces abdominal fat. In a 2024 ferret study, ipamorelin (1-3 mg/kg) inhibited chemotherapy-induced body-weight loss by about 24% — a peripheral anti-cachexia effect, not fat loss [8]. Community reports of gradually leaner body composition over weeks to months are anecdotal and confounded by diet and training, not a measured outcome.
What are the downsides of ipamorelin?
The clearest downside is the evidence gap: no approved indication, one failed Phase 2 trial [7], and no long-term human safety data. Class-level concerns include a cardiotoxicity signal from a related ghrelin-receptor agonist in rats [9] and the theoretical IGF-1/proliferation question. Community-reported downsides — flushing, appetite, tingling, puffiness — are anecdotal and listed on the effects page.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product to discontinue. Its clinical development stalled because the only Phase 2 trial, for postoperative ileus, missed its primary endpoint (time to first tolerated meal 25.3 h vs 32.6 h placebo, p=0.15) [7] and no Phase 3 followed. Separately, in 2024 the FDA tightened compounding access by removing ipamorelin acetate from the interim 503A Category 2 list.
What does CJC-1295 and ipamorelin do?
They hit two different receptors to amplify one growth-hormone pulse. CJC-1295 (a GHRH analog) acts on the GHRH receptor; ipamorelin acts on the separate ghrelin receptor [1]. A 2026 review reported the combination improved muscle tetanic tension in a mouse glucocorticoid model, while stressing the evidence is limited to animal studies [16]. No controlled human outcome trial of the combination exists.
How does CJC-1295 ipamorelin work?
The two work through complementary pathways. CJC-1295 stimulates the GHRH receptor (a cAMP signal); ipamorelin stimulates GHS-R1a, the ghrelin receptor (a calcium signal) [1]. Because the routes are distinct, co-administration is expected to produce a larger growth-hormone pulse than either alone — though this synergy is inferred from separate single-agent pharmacology, not a trial of the combination [16] [1].
How much CJC-1295 ipamorelin should I take?
There is no evidence-based dose, because no controlled human trial has tested the combination for any outcome [16]. The only published human ipamorelin doses were intravenous and lab-administered [6] [7]. Community subcutaneous stack protocols have no peer-reviewed human dosing basis and are anecdotal, not recommended [7]. This site reports study figures in third person and does not provide a personal dose.
Does CJC-1295 ipamorelin work?
For muscle and recovery, the supporting data is animal-only. A 2026 review reported the CJC-1295/ipamorelin combination improved maximum tetanic tension in a glucocorticoid muscle-loss model in mice, but emphasized the evidence is limited to animal studies and no rigorous human trials exist [16]. "Works" in a proven human sense is not supported by controlled trial data.
How to reconstitute CJC-1295 ipamorelin 5mg?
Research peptides ship as a lyophilized (freeze-dried) powder and are reconstituted with bacteriostatic water for laboratory handling; as peptides they degrade with heat and repeated freeze-thaw, so reconstituted solution is typically refrigerated [6]. These are general research-supply handling observations, not a clinical preparation instruction, and no specific volume or concentration is endorsed because there is no approved human formulation.
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin's terminal half-life is approximately 2 hours, with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [6]. By the usual five-half-life rule, that implies the compound itself is largely cleared within about 10 hours. The growth-hormone pulse it triggers peaks around 40 minutes (0.67 h) after dosing as a single discrete event [6].
Does ipamorelin make you hungry?
It can, mechanistically. Ipamorelin acts on the ghrelin receptor — the same receptor the body's hunger hormone uses — and ghrelin-receptor agonists activate the brain's appetite centers and induce feeding in animal studies [12]. Community accounts describe an uptick in appetite after injection, generally milder than with GHRP-6 [reported, anecdotal]. The effect is plausible from mechanism but not quantified in humans.
Will I gain weight on ipamorelin?
There is no human dosing protocol here and no human weight-outcome trial to cite. In mice, ipamorelin stimulated adiposity and raised leptin independently of growth hormone [11], and in a ferret cachexia model it blunted weight loss [8]. Whether a person gains weight depends on appetite, diet, and training — community reports vary and are anecdotal, not a measured outcome.
Does ipamorelin increase appetite?
Likely yes by mechanism. As a ghrelin-receptor (GHS-R1a) agonist, ipamorelin engages the same receptor that drives hunger; central administration of ghrelin-receptor agonists induces feeding and activates brain appetite centers in animals [12]. Reports describe this as milder than with the less selective GHRP-6, but it is a class-level orexigenic signal, not eliminated by ipamorelin's hormone selectivity.
What does ipamorelin peptide do?
Ipamorelin peptide activates the ghrelin receptor (GHS-R1a) on pituitary cells to release a clean pulse of growth hormone without raising cortisol [1]. In rats this drives faster longitudinal bone growth [2] and higher bone mineral content [3]. In humans, only its pharmacokinetics (half-life ~2 h) [6] and a failed ileus trial [7] are published. Reported subjective effects are anecdotal.
How long does it take for ipamorelin to work?
At the hormone level, fast: the growth-hormone pulse peaks about 40 minutes after a dose in humans [6]. At the level of reported subjective effects, community accounts describe sleep changes within one to two weeks and body-composition shifts over weeks five to twelve [reported, anecdotal]. Those timelines are not from controlled trials and should be read as anecdotal, not measured outcomes.
Does ipamorelin cause water retention?
Mild water retention is plausible and occasionally reported. Growth-hormone excess is associated with sodium and water retention physiologically, and community accounts describe transient puffiness in fingers, ankles, or face in the first two to four weeks, generally milder than with older peptides [reported, anecdotal]. The single short Phase 2 trial flagged no specific fluid-retention safety signal [7], but it was not designed to measure it.